7. March 2012 12:20
Alkermes has appointed the experienced Mark Stejbach to the newly created position of Chief Commercial Officer, and as a member of the executive management team.
Mr Stejbach will be responsible for the biohpharma company’s commercial activities for products such as Vivitrol and the commercial strategies for its late-stage pipeline.
Richard Pops, Chief Executive Officer of Alkermes, says the company hopes the new recruit will “accelerate and expand” the Dublin-based company’s commercial activities.
The 46-year-old has more than 25 years’ experience in biotech and pharmaceutical marketing, sales, managed care and finance. He most recently served in a similar role at Tengion after working as the Vice President of Managed Care Marketing at Merck & Co between 2005 and 2008.
“I am thrilled to join Alkermes at this extremely exciting time for the company, and I see tremendous potential for Vivitrol as well as the robust pipeline of new product candidates,” commented Mark Stejbach. “I look forward to enhancing the company’s commercial capabilities to achieve its ultimate goal of bringing unique and compelling medicines to patients in need.”
19. September 2011 14:01
Alkermes (ALKS) has marked its first day of operations at its new Dublin HQ with a long term multi-million dollar manufacturing contract with one of the world’s top pharma companies.
The pharma company’s finished product will be manufactured at Alkermes new Athlone facility in Ireland in a deal which could be worth up to $20m by 2016.
Richard Pops, CEO of Alkermes, said the company was “excited to have our operations based in Ireland, which we view as a gateway to the European Union and global pharmaceutical market”.
The company employs more than 450 staff based in Ireland and more than 1,200 worldwide.
The plant in Athlone is one of three facilities owned by Alkermes where the company manufactures proprietary, partnered and contract-based drug products.